Back to search results

Tislelizumab After Liver-Directed Therapy for Liver Cancer

This study is investigating whether adding Tislelizumab (an antibody that targets PD-1, a protein on immune cells) after local treatment for advanced liver cancer (hepatocellular carcinoma or HCC) can improve how long people live without their cancer growing. Researchers believe Tislelizumab might work with local treatments to fight cancer and prevent it from spreading. You might be able to join if you have HCC, are planning to receive radiation, haven't had systemic therapy for HCC before, and meet specific diagnostic criteria. The main goal is to see if Tislelizumab improves progression-free survival (how long you live without the cancer getting worse) at one year. The study will also look at safety and other outcomes. The current status of this study is unclear, and it plans to enroll 35 participants.

Study design
This is an interventional study, but the phase is not specified. It plans to enroll 35 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety for 48 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05366829

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Rutgers, The State University of New Jersey
~35 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:Tislelizumab

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety as assessed by number of participants experiencing adverse events
Measured over 48 months

Conditions

Carcinoma, Hepatocellular
Liver Cell Carcinoma

Explore related trials

Hepatocellular CarcinomaHepatitis B Infection

NCT05366829

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Montefiore Medical Center

    The Bronx, New Yorkstudy coordinator listed

    Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jerseystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Salma Jabbour, MD · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey

Who to contact

Salma Jabbour, MD
[email protected]
732-253-3961
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Each patient eligible to participate in this study must meet all the following criteria:
Calculate serum creatinine clearance using the standard Cockcroft-Gault formula.

What this trial measures

  • Safety as assessed by number of participants experiencing adverse events48 months

    Number of participants experiencing adverse events grade three or higher, as defined by Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0). Severity is a measure of intensity (eg, grade of a specific AE, mild \[Grade 1\], moderate \[Grade 2\], severe \[Grade 3\], or life-threatening \[Grade 4\]), whereas seriousness is classified by the criteria based on the regulatory definitions. Seriousness serves as the guide for defining regulatory reporting obligations from the Investigator Sponsor to applicable regulatory authorities as described in CTCAE version 5.0.